Biogenic amines in discrete brain areas after treatment with monoamineoxidase inhibitors.
D000818:Animals; D001479:Basal Ganglia / Q000032:analysis; D001923:Brain Chemistry / Q000187:drug effects*; D002531:Cerebellum / Q000032:analysis; D002540:Cerebral Cortex / Q000032:analysis; D004298:Dopamine / Q000032:analysis*; D005625:Frontal Lobe / Q000032:analysis; D007031:Hypothalamus / Q000032:analysis; D008032:Limbic System / Q000032:analysis; D008526:Medulla Oblongata / Q000032:analysis; D008636:Mesencephalon / Q000032:analysis; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009638:Norepinephrine / Q000032:analysis*; D009778:Occipital Lobe / Q000032:analysis; D011149:Pons / Q000032:analysis; D051381:Rats; D012701:Serotonin / Q000032:analysis*; D013053:Spectrophotometry; D003336:Tectum Mesencephali / Q000032:analysis; D013788:Thalamus / Q000032:analysis
D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D004298:Dopamine; D009638:Norepinephrine